Phaseline

Companies › Jecho Biopharmaceuticals

Jecho Biopharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Infectious disease; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JL18008
IL-18 receptor agonist
–Phase 1HIV InfectionsFeb 2027
JL19001–Phase 1High Risk Non-muscle Invasive Bladder Cancer; MalignanciesMar 2027
JLM019 Injection–Phase 1Advanced Solid Tumor (Phase 1)Mar 2029
JL15003 Injection–Phase 1Recurrent Glioblastoma Multiforme(GBM)Apr 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07579741JL18008Phase 1HIV InfectionsInfectious diseaseFeb 2027
NCT07483970JL19001Phase 1High Risk Non-muscle Invasive Bladder CancerOncologyMar 2027
NCT07623850JLM019 InjectionPhase 1Advanced Solid Tumor (Phase 1)OncologyMar 2029
NCT07501559JL15003 InjectionPhase 1Recurrent Glioblastoma Multiforme(GBM)OncologyApr 2030
NCT07603479JL19001Phase 1MalignanciesOncologyMay 2030

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.